NYSE:Immunovant, Inc.
График котировок Immunovant, Inc.
График IMVT предоставлен TradingView
Добавить в список сравнения
Добавить в список отслеживания
Добавить в портфель
Основные параметры
P/BV | 10.57 |
---|---|
EV/EBITDA | -47.95 |
EBITDA | -0.08 |
Цена ао | 44.1 |
Основные владельцы
Institutions | Объем | Доля, % |
---|---|---|
RTW INVESTMENTS, LLC | 7510412 | 7.67 |
Ghost Tree Capital, LLC | 525000 | 0.54 |
Defiance ETFs, LLC | 26689 | 0.03 |
Invesco Capital Management LLC | 394325 | 0.4 |
Longwood Capital Partners LLC | 250000 | 0.26 |
Heptagon Capital Limited | 199840 | 0.2 |
Bvf Inc | 1198427 | 1.22 |
Cormorant Asset Management, LLC | 1637951 | 1.67 |
AlphaCentric Advisors LLC | 2150 | 0 |
Vivo Capital, LLC | 1042460 | 1.06 |
Driehaus Capital Management (USVI) LLC | 86639 | 0.09 |
Parkman Healthcare Partners LLC | 150151 | 0.15 |
Putnam | 225600 | 0.23 |
Putnam Investment Management, LLC | 118465 | 0.12 |
PURA VIDA INVESTMENTS, LLC | 270806 | 0.28 |
Boston Management and Research | 58428 | 0.06 |
Principal Global Investors, LLC | 134438 | 0.14 |
Ikarian Capital, LLC | 321887 | 0.33 |
Camber Capital Management LLC | 438800 | 0.45 |
ALPS Advisors Inc | 157400 | 0.16 |
Pinz Capital Management, LP | 199100 | 0.2 |
Prudential Retirement Services | 65324 | 0.07 |
Mangrove Partners | 230307 | 0.24 |
BlackRock Fund Advisors | 2147508 | 2.19 |
Содержится в ETF
ETF | Доля, % | Доходность за год, % |
---|---|---|
ALPS Medical Breakthroughs ETF | 2.47 | 35.77 |
Defiance Next Gen SPAC Derived ETF | 1.64 |
Похожие компании
Описание Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.